Patient-Reported Outcomes in Advanced Urothelial Carcinoma

EP: 1.Overview of Urothelial Carcinoma: A Global Burden

EP: 2.Germline Mutations in Advanced Urothelial Carcinoma

EP: 3.Frontline Treatment Approaches for Locally Advanced Urothelial Carcinoma

EP: 4.Novel Neoadjuvant Approaches in Advanced Urothelial Carcinoma

EP: 5.I/O Adjuvant Therapy for Advanced Urothelial Carcinoma

EP: 6.Frontline Treatment for Metastatic Urothelial Carcinoma

EP: 7.Molecular Testing in Metastatic Urothelial Carcinoma

EP: 8.Second-Line Treatment for Metastatic Urothelial Carcinoma

EP: 9.Antibody-Drug Conjugates in Advanced Urothelial Carcinoma

EP: 10.Trop-2–Targeting ADC Therapy for Advanced Urothelial Carcinoma

EP: 11.Novel Sequencing Strategies for Advanced Urothelial Carcinoma

EP: 12.ADCs for Urothelial Carcinoma: Selection and AE Management

Now Viewing

EP: 13.Patient-Reported Outcomes in Advanced Urothelial Carcinoma

EP: 14.Optimizing Therapy for Patients With Advanced Urothelial Carcinoma

EP: 15.Future Directions in Advanced Urothelial Carcinoma

Petros Grivas, MD, PhD: This is a dialogue that we keep having with one another and with providers in clinic: how to optimally sequence this drug and take into account level of evidence, efficacy, safety, and medical comorbidities and toxicity profiles, which you mentioned before. I’ll quickly try to go further in this discussion before we wrap up. Regarding the importance of quality of life and patient-reported outcomes, we’ve been trying to get more data in urothelial cancer using validated tools. We’re learning from other tumor types. You’ve done studies yourselves, like the TITAN study in prostate cancer. Do you have any comments on how we can better integrate quality of life and patient-reported outcomes in the platinum-refractory and earlier settings in advanced urothelial cancer?

Neeraj Agarwal, MD: As we get more options in bladder cancer, which is a great news for all of us and our patients, we’ll be choosing therapies for our patients, or our patients will be making the decision to go with 1 therapy over another based on quality-of-life data and the adverse-effect profile. It’s a matter of time. It’s already happening, which is great news. It means we have options. When there are options, we have to pick. In that context, quality-of-life data will be very important. My only suggestion, and I know it’s already happening, is to use validated health-related quality-of-outcome tools in every phase 3 trial moving forward in bladder cancer. That should be mandated for all ongoing or upcoming studies of patients with metastatic bladder cancer, or even in neoadjuvant chemotherapy or the neoadjuvant therapy setting.

Transcript edited for clarity.